热休克蛋白HSP70和gp96增强乙肝DNA疫苗的细胞和体液免疫应答

Enhancement of cellular and humoral immune responses of HBV DNA vaccine by HSP70 and gp96

旨在以乙肝病毒（HBV）的主要结构蛋白-表面蛋白（HBsAg）和核心蛋白（HBcAg）作为抗原设计DNA疫苗,研究热休克蛋白HSP70和gp96作为新型免疫佐剂增强疫苗的细胞免疫和体液免疫水平。利用酶联免疫斑点实验、流式细胞内因子染色、3H-TdR实验、酶联免疫吸附实验技术分析,结果显示HSP70和gp96可使疫苗的细胞免疫水平提高1~6倍,提高体液免疫水平20%~60%。研究结果为设计以HSP70和gp96作为免疫佐剂的新型乙肝治疗性疫苗提供了依据。

While currently therapeutic vaccines for chronic hepatitis B virus（HBV） infection are actively being developed to complement standard antiviral treatments,their immune activity,especially T cell activity,remains to be further improved.Here,we investigated the role of heat shock proteins HSP70 and gp96 on cellular and humoral immunity,using the main structure antigens of hepatitis core（HBcAg） and surface（HBsAg） as the DNA vaccine.By ELISPOT（enzyme linked immunospot assay）,IFN-γ intracellular staining,[3H]-thymidine incorporation and ELISA（enzyme linked immunosorbent assay） analyses,we showed that immunization with HBsAg/HBcAg DNA formulation along with HSP70 or gp96 induced significant increase of T-cell（about 1-6-fold） and antibody（about 20%-60%） immunity against HBsAg and HBcAg.These results may provide bases for designing HSP70-and gp96-based vaccines aimed at eliciting T-cell responses for therapeutic applications.